Treatment Information

Back

Kidney (Renal) Cancer treatment details. Chemotherapy.

Memorial Sloan-Kettering Cancer Center, New York, New York, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:New York, New York
Treatments:ChemotherapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Sep 2004

Description:

Patients: This Phase II study involved 37 patients with advanced renal cell carcinoma, 26 men and 11 women. The median age was 64. Twenty-three patients had undergone prior nephrectomy.

Treatment: The treatment consisted of administration of a new chemotherapy agent, Bortezomib.

Toxicity: Grade 3 toxicities included constipation, dehydration, diarrhea, dyspnea, fatigue, hypercalcemeia, ileus,infection, insomnia, nausea, neuropathy, rash, and hematologic.

Results: Median survival was 7.5 months.

Correspondence: Robert Motzer, MD




Back